Searchicon: search

Nobivac® NXT FeLV

Discover the first and only non-adjuvanted feline leukemia virus (FeLV) vaccine to use RNA particle technology to generate an efficient, comprehensive immune response.

icon: feline

Product Description

Nobivac® NXT (next) FeLV is the latest innovation in feline leukemia protection. Nobivac® NXT uses revolutionary RNA particle technology to deliver safe, robust, multi-layered protection.

product Label

Features & Benefits

No extraneous material

Delivers comprehensive immunity in an adjuvant-free, preservative-free, thimerosal-free formulation

A gentle formulation

Low-volume 0.5-mL dose for a better overall vaccine experience

Robust efficacy

Next-level protection1

Multi-layered protection

Stimulates a complete immune system response with an extended, 2-year duration of immunity

How It Works

Discover the science behind Nobivac® NXT-level RNA particle technology. See how this revolutionary new way of delivering protection provides an exciting new option for you and your patients.

Product Specifications

Administration

For primary immunization, administer 1 dose (0.5-mL) subcutaneously as early as 8 weeks of age followed by a second dose administered 3 to 4 weeks later

Indication

Effective for vaccination of healthy cats, 8 weeks of age or older, against feline leukemia virus. The duration of immunity is at least 2 years. Also shown to be effective against persistent viremia in cats exposed to virulent feline leukemia virus

Supplied

25 doses per tray

Safety

Safe in kittens as young as 8 weeks of age4

Disease Information

FELINE LEUKEMIA VIRUS (FELV)

FeLV is a retrovirus that replicates within many tissues, including bone marrow, salivary glands, and respiratory epithelium.2
The percentage of cats infected with FeLV varies depending on age, health, environment, and lifestyle.3

TRANSMISSION

FeLV in saliva, nasal secretions, urine, and feces can be transmitted during intimate contact with infected cats. Kittens can acquire the virus from infected mothers while still in the womb or through nursing.3

Bite wounds, mutual grooming, and rarely sharing food or water dishes are all means of transmission.3

CLINICAL SIGNS

FeLV does not result in predictable clinical signs. Rather the clinical signs vary depending on the course of infection in the individual cat.
Common examples may include:

  • Fever
  • Loss of appetite
  • Weight loss
  • Diarrhea
  • Swollen lymph nodes
  • Pale or inflamed gums

RISK FACTORS

  • Lives in a multiple cat household
  • Is a rescue cat or from a feral cat population
  • Kittens are at higher risk of infection than adult cats3
  • Outdoor cats are at higher risk
  • Unvaccinated cats

NOBIVAC® NXT-GENERATION PROTECTION

Learn more about Nobivac® NXT technology, the latest vaccine platform from Nobivac®.

LEARN MORE

All trademarks are property of their respective owners.

References

  1. Carritt K, Davis R, Stachura K, Mogler M, Xu Z, Tarpey I. An RNA particle vaccine expressing feline leukemia virus envelope protein protects against virulent FeLV challenge. Abstract presented at: ISCAID Symposium 2024; October 14-16, 2024; Vancouver, Canada.
  2. Sykes J. Greene’s Infectious Diseases of the Dog and Cat, 5th ed. Elsevier; 2023:382-413
  3. Cornell University College of Veterinary Medicine Feline Health Center. Feline leukemia virus brochure. Accessed August 19, 2024. https://www.vet.cornell.edu/departments-centers- and-institutes/cornell-feline-health-center/health-information/feline-health-topics/feline-leukemia-virus-brochure
  4. Nobivac® NXT FeLV. Product Label. Merck Animal Health.